Enzo Biochem (NYSE: ENZ) may have some royalty payments coming Print
By M.E.Garza   
Monday, 01 March 2010 10:17

Stumbled upon some interesting information on the U.S. Patent web site.

It appears that Enzo Biochem (NYSE: ENZ) won its patent interference case against Chiron, now Bayer HealthCare LLC, which  now makes Enzo Biochem the senior party.

The implication of this news is far reaching for Enzo Biochem, given that Chiron has infringed on Enzo.

The current sales on products that infringe are worth an estimated $100 million per year and if one assumes a mid-single digit royalty, that would be worth an estimated $5-7 million per year to Enzo Biochem for at least the next 17 years.

Once news hits about this in a bigger way, then all bets are off.  Just posting this in case some of our readers who like speculative trades can get ahead of it.

Disclosure: Long ENZ

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus